Background: Data for predicting severity of patients with COVID-19 infection are sparse and still under investigation. We retrospectively studied whether the admission serum C-reactive protein level (CRP) can serve as nearly predictor of disease severity during COVID-19 infection in comparison with other hematologic and inflammatory markers. Methods: We included all consecutive patients who were admitted in Cheikh Khalifa International University Hospital, Casablanca, Morocco, between February to April 2020, with a confirmed diagnosis of COVID-19 infection using SARS-CoV-2 viral nucleic acid via RT-PCR. The complete blood count and serum CRP level were routinely measured on admission. All clinical and laboratory data of patients were collected and analyzed. The classification of the disease severity was in accordance with the clinical classification of the WHO interim guidance, and the management of patients were adapted to the national management guideline. We estimated receiver operating characteristic (ROC) curves of blood routine parameters as well as their association with COVID-19 disease severity. Results: 145 COVID-19 patients were included in the study. The median age (range) was 50 (32-63) years, and Kratak sadr`aj Uvod: Podaci za predvi|anje te`ine stanja pacijenata sa infekcijom COVID-19 su retki i jo{ uvek se istra`uju. Retrospektivno smo istra`ili da li nivo C-reaktivnog proteina (CRP) mo`e da poslu`i kao rani indikator ozbiljnosti bolesti pri infekciji virusom COVID-19 u pore|enju sa drugim hematolo{kim i upalnim markerima. Metode: Uklju~ili smo sve pacijente koji su uzastopno primljeni u Me|unarodnu univerzitetsku bolnicu [eik Kalifa u Kazablanki, Maroko, u periodu od februara do aprila 2020. godine, sa dijagnozom COVID-19 infekcije potvr -|enom pomo u virusne nukleinske kiseline COVID-19 putem RT-PCR. Kompletna krvna slika i nivo seruma CRP rutinski su mereni na prijemu. Svi klini~ki i laboratorijski podaci pacijenata su prikupljeni i analizirani. Klasifikacija te`ine bolesti bila je u skladu sa klini~kom klasifikacijom privremenih uputstava SZO, a le~enje pacijenata prilago -|eno me|unarodnim smernicama. Izvr{ili smo procenu ROC krive parametara analize krvi kao i njihovu povezanost sa te`inom bolesti COVID-19. Rezultati: U istra`ivanje je uklju~eno 145 pacijenata sa infekcijom COVID-19. Srednja vrednost starosti bila je 50 godina (32-63 godine), a 75 pacijenata (51,7%) bili su mu{karci. U lak{u grupu svrstan je 101 pacijent, a u te`u
Extramedullary plasmacytoma (EMP) is an uncommon plasma cell neoplasm results from plasma cell proliferation and consists of monoclonal plasmacytic infiltration, without bone marrow involvement and any other systemic characteristics of multiple myeloma. EMP accounts for 3% of all plasma cell neoplasms and approximately 80% to 90% of EMP involve submucosa of the upper aerodigestive, while scrotal, dermis and retroperitoneal infiltration are very rare. There are no consensus guidelines for treatment, but EMP is highly radiosensitive, surgery may be considered for some sites, but 11 at 30% can progress in multiple myeloma. We report here an exceptional case of recurrent EMP in much localization. It's about a man 72 years old with initially testicular plasmocytoma who generalized the plasmacytic infiltration after 16 months in skin and progressively in mediastinal and retroperitoneal plasmacytoma, without any medullar and bone involvement.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.